Efficacy and safety of atezolizumab compared to docetaxel in non-small cell lung cancer patients regardless of PD-L1 status: a systematic review and meta-analysis
Atezolizumab showed OS improvement and great safety in NSCLC. There was no direct relationship between the effectiveness of atezolizumab and PD-L1 expression status. The safety and maintenance of efficacy remain undetermined, and further research is needed to explore the long-term effectiveness of atezolizumab.
Authors
- Yonghong Cui
- Hai Zhao (ORCID: https://orcid.org/0000-0002-3392-2584)
- Ximing Li (ORCID: https://orcid.org/0000-0003-4287-3152)
Institutions
- China National Pharmaceutical Group Corporation (China) (CN)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/cco-25-45
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00